<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p50" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_50{left:130px;bottom:1195px;letter-spacing:0.21px;}
#t2_50{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_50{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_50{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_50{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_50{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_50{left:238px;bottom:1037px;letter-spacing:-0.01px;}
#t8_50{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#t9_50{left:238px;bottom:999px;letter-spacing:-0.01px;}
#ta_50{left:238px;bottom:944px;letter-spacing:-0.01px;}
#tb_50{left:238px;bottom:925px;letter-spacing:-0.01px;}
#tc_50{left:238px;bottom:906px;letter-spacing:-0.01px;}
#td_50{left:238px;bottom:886px;letter-spacing:-0.01px;}
#te_50{left:238px;bottom:867px;letter-spacing:-0.01px;}
#tf_50{left:238px;bottom:847px;letter-spacing:-0.01px;}
#tg_50{left:238px;bottom:828px;letter-spacing:-0.01px;}
#th_50{left:238px;bottom:808px;letter-spacing:-0.01px;}
#ti_50{left:238px;bottom:789px;letter-spacing:-0.01px;}
#tj_50{left:238px;bottom:770px;letter-spacing:-0.01px;}
#tk_50{left:238px;bottom:750px;letter-spacing:-0.01px;}
#tl_50{left:238px;bottom:731px;letter-spacing:-0.01px;}
#tm_50{left:238px;bottom:711px;letter-spacing:-0.01px;}
#tn_50{left:238px;bottom:692px;letter-spacing:-0.01px;}
#to_50{left:238px;bottom:672px;letter-spacing:-0.01px;}
#tp_50{left:238px;bottom:653px;letter-spacing:-0.01px;}
#tq_50{left:238px;bottom:633px;letter-spacing:-0.01px;}
#tr_50{left:238px;bottom:614px;letter-spacing:-0.01px;}
#ts_50{left:238px;bottom:483px;letter-spacing:0.1px;}
#tt_50{left:238px;bottom:463px;letter-spacing:0.1px;}
#tu_50{left:238px;bottom:444px;letter-spacing:0.1px;}
#tv_50{left:347px;bottom:444px;letter-spacing:0.1px;}
#tw_50{left:238px;bottom:409px;letter-spacing:-0.01px;}
#tx_50{left:238px;bottom:389px;letter-spacing:-0.01px;}
#ty_50{left:238px;bottom:370px;letter-spacing:-0.01px;}
#tz_50{left:238px;bottom:335px;letter-spacing:-0.01px;}
#t10_50{left:238px;bottom:316px;letter-spacing:-0.01px;}
#t11_50{left:445px;bottom:316px;letter-spacing:-0.01px;}
#t12_50{left:496px;bottom:316px;}
#t13_50{left:238px;bottom:281px;letter-spacing:-0.01px;}
#t14_50{left:238px;bottom:261px;letter-spacing:-0.01px;}
#t15_50{left:238px;bottom:242px;letter-spacing:-0.01px;}
#t16_50{left:238px;bottom:223px;letter-spacing:-0.01px;}
#t17_50{left:238px;bottom:203px;letter-spacing:-0.01px;}
#t18_50{left:238px;bottom:184px;letter-spacing:-0.01px;}
#t19_50{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_50{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_50{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_50{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_50{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s4_50{font-size:13px;font-family:NotoSans-Regular_7j-;color:#F78C00;}
.s5_50{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts50" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg50Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg50" style="-webkit-user-select: none;"><object width="908" height="1286" data="50/50.svg" type="image/svg+xml" id="pdf50" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_50" class="t s0_50">6.7 Patient information / education </span><span id="t2_50" class="t s1_50">50 </span>
<span id="t3_50" class="t s2_50">appropriately illustrated, standardized information sheets are used to support the oral </span>
<span id="t4_50" class="t s2_50">information, which is obligatory in all cases. In order to document the oral information given to </span>
<span id="t5_50" class="t s2_50">the patient, it is essential that it be entered in the medical records. According to the Patient </span>
<span id="t6_50" class="t s2_50">Rights Act, the patient must be given a copy of the information sheet [141]. The content of the </span>
<span id="t7_50" class="t s2_50">information depends on the type of treatment; the radio-oncologist is responsible for providing </span>
<span id="t8_50" class="t s2_50">information about primary radiotherapy. The ear, nose and throat specialist is responsible for </span>
<span id="t9_50" class="t s2_50">providing information about surgical treatment. </span>
<span id="ta_50" class="t s2_50">When treating primary tumors, a differentiation must be made, which includes both transoral </span>
<span id="tb_50" class="t s2_50">laser surgery and transcervical surgery. The exact location of the tumor must also be taken into </span>
<span id="tc_50" class="t s2_50">account, whereby the three levels, the subglottis, the glottis and the supraglottis, must be </span>
<span id="td_50" class="t s2_50">treated separately. In addition to treating the primary tumor, the patient must also be informed </span>
<span id="te_50" class="t s2_50">about the treatment of the lymphatic drainage routes. The need for an elective neck dissection </span>
<span id="tf_50" class="t s2_50">as well as a therapeutic neck dissection must be fully explained to the patient. The patient must </span>
<span id="tg_50" class="t s2_50">be informed that after the primary tumor has been treated, changes to the treatment </span>
<span id="th_50" class="t s2_50">recommendations are possible, taking into account the histological findings available at that </span>
<span id="ti_50" class="t s2_50">time. These must then be explained again. Furthermore, in the case of a partial resection of the </span>
<span id="tj_50" class="t s2_50">larynx, the temporary tracheotomy, which is sometimes necessary, must be discussed in detail </span>
<span id="tk_50" class="t s2_50">with the patient. Since in many cases adjuvant therapy in the form of radiochemotherapy is </span>
<span id="tl_50" class="t s2_50">necessary in addition to surgical treatment for extensive tumors, particularly in cases of proven </span>
<span id="tm_50" class="t s2_50">lymph node metastasis, the patient must also be informed of this. In particular, it must be </span>
<span id="tn_50" class="t s2_50">explained to the patient why adjuvant therapy in the form of radiation and chemotherapy is </span>
<span id="to_50" class="t s2_50">necessary despite the surgical removal of the tumor. Chemotherapy accompanying </span>
<span id="tp_50" class="t s2_50">radiotherapy has become established in recent years, and patients must be informed in detail </span>
<span id="tq_50" class="t s2_50">by the internal oncologist about the benefits of this additional treatment, with an explanation </span>
<span id="tr_50" class="t s2_50">of the corresponding side effects. </span>
<span id="ts_50" class="t s1_50">The doctor providing the information should also consider how the patient is able to </span>
<span id="tt_50" class="t s1_50">psychologically process the information provided. He should counteract irrational “subjective </span>
<span id="tu_50" class="t s1_50">theories of illness” </span><span id="tv_50" class="t s1_50">[142]. </span>
<span id="tw_50" class="t s3_50">Despite truthful information, hope can be conveyed even in the case of an unfavourable </span>
<span id="tx_50" class="t s3_50">prognosis, if necessary through information about palliative </span>
<span id="ty_50" class="t s3_50">Treatment options. </span>
<span id="tz_50" class="t s3_50">Psycho-oncologically experienced staff can be helpful for psychologically stressed patients </span>
<span id="t10_50" class="t s3_50">and/or their relatives (see chapter</span><span id="t11_50" class="t s4_50">7.10.3.2 </span><span id="t12_50" class="t s2_50">). </span>
<span id="t13_50" class="t s3_50">In clinical trials, the patient must be informed in detail about the content of the study in </span>
<span id="t14_50" class="t s3_50">advance and must of course be free to decide whether he or she is available for a </span>
<span id="t15_50" class="t s3_50">corresponding study. If tissue is to be preserved in tumor biobanks, the patient must also be </span>
<span id="t16_50" class="t s3_50">given detailed information. The treating physician must explain to the patient the advantages </span>
<span id="t17_50" class="t s3_50">of such a biobank for future research projects. It must also be explained to the patient that this </span>
<span id="t18_50" class="t s3_50">will enable further future research projects [143]. </span>
<span id="t19_50" class="t s5_50">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
